Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Cailin T Collins, Yusuke Nakauchi, Thomas Koehnke, James S Chavez, Suyoun Choi, Rajiv Sharma, Feifei Zhao, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 953.

https://doi.org/10.1182/blood-2023-187422

Published: 2023

Journal Articles

Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

Basil Allen, Daniel Bottomly, Anthony Wang, Thomas Koehnke, Lindsey Savoy, Peter Ryabini, Reid Chen, Kara Johnson, Stephen E. Kurtz, Anupriya Agarwal, Michelle Barton, Brian J. Druker, Ravi Majeti, Jeffrey W Tyner, Shannon K McWeeney, Haijiao Zhang

Blood (2023) 142 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2023-178096

Published: 2023

Journal Articles

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Thomas Koehnke, Daiki Karigane, Eleanor Hilgart, Kensuke Kayamori, Amy C Fan, Cailin T Collins, Fabian P Suchy, Athreya S Rangavajhula, Yang Feng, Yusuke Nakauchi, Eduardo Martinez-Montes, Michael Koldobskiy, Andy Feinberg, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 579.

https://doi.org/10.1182/blood-2023-186440

Published: 2023

Journal Articles

ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack

Blood (2023) 142 (Supplement 1): 364.

https://doi.org/10.1182/blood-2023-189177

Published: 2023

Journal Articles

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Daiki Karigane, Amy C Fan, Kensuke Kayamori, Yusuke Nakauchi, Thomas Koehnke, Athreya S Rangavajhula, Asiri Ediriwickrema, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 406.

https://doi.org/10.1182/blood-2023-181430

Published: 2023

Journal Articles

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Brian Chernak, Marta Galan-Diez, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Ziwei Chen, Thomas Koehnke, Ravindra Majeti, Martin Carroll, Azra Raza, Stavroula Kousteni

Blood (2023) 142 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2023-174485

Published: 2023

Journal Articles

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Kendra K Jackson, Amy C Fan, Daiki Karigane, Feifei Zhao, Cailin T Collins, Yusuke Nakauchi, Kensuke Kayamori, Athreya S Rangavajhula, Thomas Koehnke, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 946.

https://doi.org/10.1182/blood-2023-187865

Published: 2023

Journal Articles

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Maryam Kazerani, Lucas Wange, Benjamin Tast, Maria Solovey, Daniel Nixdorf, Lisa Rohrbacher, Christina Heitmüller, Thomas Koehnke, Frauke Schnorfeil, Victoria V Grunwald, Karsten Spiekermann, Klaus H. Metzeler, Karl-Peter Hopfner, Wolfgang Enard, Veit L Buecklein, Marion Subklewe

Blood (2022) 140 (Supplement 1): 6321–6322.

https://doi.org/10.1182/blood-2022-167788

Published: 2022

Journal Articles

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Niklas Landberg, Thomas Koehnke, Yusuke Nakauchi, Amy Fan, Daiki Karigane, Daniel Thomas, Ravindra Majeti

Blood (2022) 140 (Supplement 1): 2234–2235.

https://doi.org/10.1182/blood-2022-159617

Published: 2022

Journal Articles

Chromatin Accessibility Analysis Reveals Epigenetic Evolution Is a Common Mechanism of Relapse in Acute Myeloid Leukemia

Kevin A. Nuno, Armon Azizi, Thomas Koehnke, Asiri Ediriwickrema, M. Ryan Corces, Ravi Majeti

Blood (2021) 138 (Supplement 1): 677.

https://doi.org/10.1182/blood-2021-148928

Published: 2021

Journal Articles

Multi-Omic Analysis Identifies Epigenetic Evolution in Relapsed Acute Myeloid Leukemia

Kevin Nuno, BS, Armon Azizi, BS, Thomas Koehnke, MD, M. Ryan Corces, PhD, Ravi Majeti, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-143141

Published: 2020

Journal Articles

Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies

Thomas Koehnke, MD, Rajiv Sharma, PhD, Yusuke Nakauchi, MD PhD, Andreas Reinisch, MD PhD, Ravi Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 820.

https://doi.org/10.1182/blood-2019-130528

Published: 2019

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

Yusuke Nakauchi, MD PhD, Daniel Thomas, MD PhD, Rajiv Sharma, PhD, M. Ryan Corces, PhD, Andreas Reinisch, MD PhD, David Cruz, MS, Thomas Koehnke, MD PhD, Daiki Karigane, MDPhD, Amy Fan, BS, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 887.

https://doi.org/10.1182/blood-2018-99-113907

Published: 2018

Journal Articles

Identification of Novel Targets for Antibody or Chimeric Antigen Receptor (CAR) Based Immunotherapy in AML: Characterizing the Surfaceome from Primary Patient Samples

Thomas Koehnke, MD, Liu Xilong, Sascha Haubner, MD, Christina Krupka, PhD, Victor Solis-Mezarino, Franz Herzog, PhD, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 3968.

https://doi.org/10.1182/blood.V130.Suppl_1.3968.3968

Published: 2017

Journal Articles

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Bettina Lindl, Christina Krupka, PhD, Tara Chapman-Arvedson, Roman Kischel, MD, Peter Kufer, MD, Sascha Haubner, MD, Felix S. Lichtenegger, MD, Thomas Koehnke, MD, Klaus H. Metzeler, MD, Nikola Konstandin, PhD, Karsten Spiekermann, Wolfgang Hiddemann, MD PhD, Marion Subklewe, MD

Blood (2017) 130 (Supplement 1): 2656.

https://doi.org/10.1182/blood.V130.Suppl_1.2656.2656

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Veit Bücklein, MD, Thomas Koehnke, MD, Sandra Rechkemmer, Frauke Schnorfeil, PhD, Stephanie Schneider, PhD, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Cristina Sauerland, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 5081.

https://doi.org/10.1182/blood.V130.Suppl_1.5081.5081

Published: 2017

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

NARROW

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Chromatin Accessibility Analysis Reveals Epigenetic Evolution Is a Common Mechanism of Relapse in Acute Myeloid Leukemia

Multi-Omic Analysis Identifies Epigenetic Evolution in Relapsed Acute Myeloid Leukemia

Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

Identification of Novel Targets for Antibody or Chimeric Antigen Receptor (CAR) Based Immunotherapy in AML: Characterizing the Surfaceome from Primary Patient Samples

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only